FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The results of this study showed that PDE-5i use was not associated with a decrease in PC cancer (OR 0.90, 95% CI 0.68 – 1.20, p = 0.476), low grade disease (OR 0.93, 95% CI 0.67-1.27, p=0.632) or high grade disease (OR 0.85, 95% CI 0.51 – 1 39, p=0.508). When looking at the secondary analysis of North American men, there was an inverse trend between PDE-5i use and PC diagnosis, however there was no statistically significant results (OR 0.67, 95% CI 0.42 – 1.07, p = 0.091). The limitations in the study were: PDE-5i use was not randomly assigned and the use rate was low, PDE-5i use was self-reported so some factors were unable to control, the study was only limited to white men, and the study period was limited to 4-years.
In conclusion, PDE-5I was not associated with decrease PC based on post-hoc analysis of REDUCE. There was an inverse relationship between PDE-5i and PC diagnosis in North American men, but it did not reach statistically significance. The study recommends future studies to further determine the association between PDE-5i and PC with longer follow-up and larger study populations.
Authors: Juzar Jamnagerwalla, Lauren E. Howard, Adriana C. Vidal, Daniel M. Moreira, Ramiro Castro-Santamaria, Gerald L. Andriole and Stephen J. Freedland
Affiliations: Division of Urology, Department of Surgery, Cedars-Sinai Medical Center (JJ, ACV, SJF), Los Angeles, California, Department of Biostatistics and Bioinformatics, Duke University (LEH) and Surgery Section, Durham Veterans Affairs Medical Center (SJF, LEH), Durham, North Carolina, Department of Urology, Mayo Clinic (DMM), Rochester, Minnesota, Research and Development, GlaxoSmithKline, Inc. (RC-S), King of Prussia, Pennsylvania, and Washington University School of Medicine in St. Louis (GLA), St. Louis, Missouri
Read the Abstract
1. Lewis RW, Fugl-Meyer KS, Corona G et al: Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med 2010; 7: 1598.
2. Brock GB, McMahon CG, Chen KK et al: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332.
3. Hellstrom WJ, Gittelman M, Karlin G et al: Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003; 61: 8.
4. Sadovsky R, Miller T, Moskowitz M et al: Threeyear update of sildenafil citrate (Viagra) efficacy and safety. Int J Clin Pract 2001; 55: 115.
5. Michl U, Molfenter F, Graefen M et al: Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy. J Urol 2015; 193: 479.
6. Gallina A, Bianchi M, Gandaglia G et al: A detailed analysis of the association between postoperative phosphodiesterase type 5 inhibitor use and the risk of biochemical recurrence after radical prostatectomy. Eur Urol 2015; 68: 750.
7. Loeb S, Folkvaljon Y, Robinson D et al: Phosphodiesterase type 5 inhibitor use and disease recurrence after prostate cancer treatment. Eur Urol 2015. http://dx.doi.org/10.1016/j.eururo.2015.12.013.
8. Chavez AH, Scott Coffield K, Hasan Rajab M et al: Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis. Asian J Androl 2013; 15: 246.
9. Andriole G, Bostwick D, Brawley O et al: Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004; 172: 1314.